ENDOMETRIAL NEOPLASMS

This is the first human trial of a new experimental cancer drug called LY4175408. It is designed to target and deliver a toxic payload specifically to cancer cells that have a certain marker (PTK7). The study will test the drug's safety, side effects, and early signs of effective…

This trial is testing if an existing immunotherapy drug called atezolizumab can help control rare cancers or common cancers with rare genetic features. It will involve about 30 adults and children whose cancers have specific genetic markers. The goal is to see if this approved dr…

This study is testing a new targeted radiation treatment called LY4257496 for people with advanced cancers that have a specific protein (GRPR). The main goals are to find a safe dose and see if the treatment helps shrink tumors. It is for adults with certain advanced breast, pros…

This study is testing an experimental pill called LY3537982 for people with advanced cancers that have a specific genetic change called KRAS G12C. The research aims to find the safest and most effective dose, both alone and combined with other cancer drugs, for patients with lung…

This is the first study in people to test a new oral drug called NKT3964. It aims to see if the drug is safe and can help control advanced cancers that have spread and stopped responding to standard treatments. The study will enroll adults with specific advanced solid tumors, inc…

This is the first study in people to test a new targeted cancer drug called LY4170156. It aims to find a safe dose and see if it can help control advanced cancers, including ovarian, lung, breast, and pancreatic cancers. The study will also test the drug in combination with other…

This is the first human study of an experimental cancer drug called DM002 for people with advanced solid tumors including ovarian, prostate, endometrial, and colorectal cancers. The study has two parts: first finding the safest dose, then testing that dose to see how well it work…

This study is a national registry that will follow nearly 2,000 patients in Germany with advanced ovarian or endometrial cancer for up to three years. Its purpose is to document the real-world treatments patients receive, track how the disease progresses, and measure their qualit…